Clinical trial
A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines
NCT02353871 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Double Blind, Randomised, Placebo Controlled Study To Assess The Efficacy And Safety Of A Single Treatment Of Clostridium Botulinum Toxin Type A To Improve The Appearance Of Moderate To Severe Glabellar Lines
- Lead sponsor
- Ipsen
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- January 31, 2015
- Completion date
- August 31, 2015
- Enrollment
- 185 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
moderate to severe glabellar lines